IM Cannabis (IMCC) EBITDA (2020 - 2026)

IM Cannabis' EBITDA history runs 7 years deep, the most recent figure standing at -$1.2 million for Q1 2026.

• On a quarterly basis, EBITDA fell 1209.91% year-over-year to -$1.2 million in Q1 2026; TTM through Mar 2026 was -$9.6 million, a 46.68% increase from a year earlier, with the FY2025 full-year figure at -$8.3 million, down 11.16% from the prior year.
• EBITDA advanced to -$1.2 million in Q1 2026 per IMCC's latest filing, from -$11.1 million in the prior quarter.
• Across five years, EBITDA topped out at $2.8 million in Q3 2025 and bottomed at -$98.3 million in Q3 2022.
• The 5-year median for EBITDA is -$2.5 million (2024), against an average of -$10.5 million.
• Across the five-year window, EBITDA slumped 2087.26% in 2022 and surged 454.08% in 2025, its largest moves.
• Year by year, EBITDA stood at -$24.6 million in 2022, then soared by 81.86% to -$4.5 million in 2023, then slumped by 233.05% to -$14.9 million in 2024, then gained by 25.46% to -$11.1 million in 2025, then soared by 88.98% to -$1.2 million in 2026.
• Per Business Quant, the three latest IMCC EBITDA figures stand at -$1.2 million (Q1 2026), -$11.1 million (Q4 2025), and $2.8 million (Q3 2025).